Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 1Lymphoma 1

Interventions

pegfilgrastim 13Filgrastim 13Cytarabine 5Cyclophosphamide 5pegylated granulocyte colony-stimulating factor 4Etoposide 4Methotrexate 3Doxorubicin 3Docetaxel 3trifluridine tipiracil drug combination 2Vincristine 2Daunorubicin 2Cisplatin 2Amifostine 2trilaciclib 1niraparib 1lintuzumab 1leridistim 1isavuconazole 1fludarabine phosphate 1fish oil triglycerides 1etoposide phosphate 1eravacycline 1eflapegrastim 1angiotensin I (1-7) 1Voriconazole 1Vegetables 1Topotecan 1Thioguanine 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neutropenia × eflapegrastim × Clear all
NCT01724866 2022-04-15

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
148 enrolled 45 charts

Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡